ASAI3: What Happened to Assaí's Debt and Sales in Q3 2026

For ASAI3 shareholders, the earnings report brought both good news and a caveat. Assaí reported to Brazil's securities regulator, the CVM, that its debt relative to operating profit fell significantly, but same-store sales practically stood still. The improvement is in the balance sheet, not yet in retail demand.

What Happened to ASAI3 Stock?

Nothing is halted or missing: ASAI3 continues to trade. It closed the November 5 session at R$ 8.44, up 4.20% on the day and down 5.70% over 12 months. What changed was the earnings release. Assaí delivered its Q3 2026 earnings report to the CVM at 7:13 PM that day, after the market closed. The 4.20% gain happened before any numbers were public, and the market's reaction to the results only appears in subsequent trading sessions.

The report shows gross revenue of R$ 21.3 billion, up 2.7% from Q3 2025. Adjusted EBITDA reached R$ 1.1 billion, with the margin stable at 5.7%. Recurring net income was R$ 248 million, while accounting net income came in at R$ 427 million. Both figures exclude IFRS 16, the standard the company uses to reflect its core operations. The company held a webcast with analysts on Friday, November 6, at 11:00 AM. The key question is whether the debt reduction is real.

Did Assaí's Debt Really Fall?

Yes, and that is the strongest part of the report. Leverage—calculated in the release as net debt plus discounted receivables divided by adjusted EBITDA—dropped on both a year-over-year and quarter-over-quarter basis.

The company attributes the drop to operating cash generation of R$ 3.3 billion over the last 12 months. Net debt fell by R$ 1.3 billion over the period, driven by two factors cited in the release: lower capital expenditures and a 27.3% higher trailing EBITDA. Another movement weighs on the math: discounted receivables, which Assaí anticipates with banks, fell from R$ 2.0 billion in Q3 2025 to R$ 1.2 billion. Because this item is factored into leverage, reducing it amounts to uncompromised deleveraging. Total cash and cash equivalents closed at R$ 6.8 billion, up 12.2% from Q3 2025.

There is a nuance. The release notes that the 27.3% increase in trailing EBITDA includes tax credits, whereas the quarterly EBITDA of R$ 1.1 billion excludes PIS/COFINS credits. These are different criteria, and part of the improvement in the trailing metric relies on these credits. The excerpt of the document we reviewed also does not mention asset sales, a topic JPMorgan highlighted as a buying catalyst for the stock in October, as we covered in our analysis of the bank's view on asset sales. Debt is coming down, therefore, primarily through operational cash flow.

What About Sales? The Lagging Side

Same-store sales rose just 0.1% compared to Q3 2025, after excluding a -0.3 percentage point calendar effect, according to the release. Gross revenue grew 2.7% because the gains came from outside the existing store base, though the available excerpt does not detail where. Customer traffic rose 2.1%, with more than 40 million shoppers per month, and same-store market share held steady at 30.0% year-to-date. Assaí did not lose ground, but it didn't gain any either.

Margins held up through other means. The gross margin rose 0.45 percentage points (excluding PIS/COFINS credits), and expenses grew 0.2 percentage points below 12-month inflation. With sales flat, cost control was what kept the EBITDA margin at 5.7%.

The company points to October as a turning point, reporting its best same-store sales performance in 15 months, which it links to its anniversary promotional campaign and changes in sports betting regulations. The release also mentions a "+9.3% same-store sales growth over the last 24 months" alongside October, but the excerpt does not clarify the comparison base. That figure cannot be interpreted as growth for the month alone. One good month does not make a trend, and the quarterly results themselves demonstrate that.

Is Net Income R$ 427 Million or R$ 248 Million?

Both, because they measure different things. Recurring net income of R$ 248 million includes recurring PIS/COFINS tax credits at a base rate of 34%, according to the release notes. Accounting net income of R$ 427 million is R$ 179 million higher. The excerpt does not explain the composition of this difference. For evaluating the stock, the recurring figure is the more prudent metric, as it shows what operations tend to repeat, whereas the accounting figure may include non-recurring items. The release lists the effects of regulation and taxation on PIS/COFINS credits among its risks.

Are New Business Lines Weighing on Results Yet?

There are no numbers yet to show that. Assaí highlights several new ventures in the release: pharmacies (11 stores in São Paulo with a target of 250, though no timeline was provided), private-label brands (140 SKUs, with an expectation of reaching 250 by December), and Assaí Pets, scheduled for Q4 2026. It also reported that last-mile delivery sales grew 204% over Q3 2025 and that the spinoff of financial services with FIC is awaiting central bank approval. Dietary supplements are now available in 300 stores. The earnings excerpt does not provide revenue or margin data for these segments, meaning they remain part of the investment thesis rather than drivers. The quarter's results came from the traditional wholesale business.

What Does This Change for ASAI3 Shareholders?

The earnings report reduces financial risk, which tends to be most relevant when interest rates are high and consumers are indebted—the exact headwinds the company itself points out. However, without same-store sales growth, the bull case still depends on a retail turnaround that the quarter only hints at.

• Leverage falling compared to both the prior year and Q2 2026, with fewer discounted receivables and higher cash reserves.
• Operating expenses growing below inflation and a stable EBITDA margin, despite flat sales.
• October highlighted by the company as its best same-store sales month in 15 months.
• Same-store sales virtually flat for the quarter, with market share stable and no gains.
• Part of the trailing EBITDA improvement relies on tax credits subject to regulatory risk.
• Accounting net income significantly higher than recurring income, without detailed explanation in the release excerpt.

In upcoming earnings reports, investors should monitor three things: whether same-store sales begin to grow and whether October proves to be an outlier; whether leverage remains below current levels without relying on tax credits; and whether pharmacies and private labels start showing up in the financial data. Sendas also approved a new share buyback program, which we break down in our analysis of Sendas's approved buyback program.